Navigation Links
Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR

g statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the Company will complete enrollment of clinical trials or announce trial results in the time expected; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the results of preclinical studies such as those described in this press release will be indicative of results that may be obtained in clinical trials; whether the Company's collaborations with Novartis and Merck will be successful; whether the patents and patent applications owned or licensed by Idera will protect the Company's technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund product development and clinical trials; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Annual Report on Form 10-K filed on March 30, 2007, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

Nexavar(R) is a registered trademark of Onyx Pharmaceuticals and Bayer Corporation.

Contact

Idera Ph
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/2/2014)... Brooklyn, PA (PRWEB) October 02, 2014 ... through social engineering announced today it will host a ... The webinar will reveal the final outcome of ... at DEF CON 22 in Las Vegas and explore ... evolving social engineering attacks. To register for the ...
(Date:10/2/2014)... is a distinguished bamboo product manufacturer and retailer. Plenty ... global customers in the past few years. Now, the ... All its online workers are professional and patient; they ... company has recently added a new assortment of ... marketing specialist has announced that all these brand new ...
(Date:10/2/2014)... may interact with stress to trigger heart disease in some ... in about 13 percent of people, but only in those ... their heart disease risk through simple measures such as ... researchers said. The study authors analyzed genetic data from ... in the EBF1 gene and higher levels of central obesity, ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... literally -- may face an increased risk of dying in the ... over 3,000 older Americans, researchers found those who were unable to ... three times as likely to die in the next five years, ... anosmia -- the inability to distinguish odors -- was a bigger ...
(Date:10/1/2014)... Psychiatry researchers from the University of Adelaide have developed ... likelihood of a good outcome from treatment - from ... based on a range of factors, including clinical symptoms, ... biomarkers in the patient,s blood. , Speaking in the ... the University,s Head of Psychiatry , Professor ...
Breaking Medicine News(10 mins):Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 2Health News:Social-Engineer, Inc. Announces DEF CON 22 Capture the Flag Results in a Complimentary Webinar 3Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2
... PITTSBURGH, Jan. 18 Family caregivers who had not ... nearly two weeks longer to decide to forego further ... the issues, according to researchers from the University of ... Public Health. They share their findings in a poster ...
... , AMES, Iowa -- Parents may have good reason ... have been spending playing their new video games since ... team -- including an Iowa State University psychologist -- ... and that greater amounts of gaming, lower social competence ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) investigators Lewis ... awarded the distinction of AAAS Fellows by the American Association ... members to be recognized this year for their distinguished efforts ... AAAS Annual Meeting in February. Chief of BIDMC,s Division ...
... in particular the CAMERA study, has used MRI to study ... higher proportion of these patients exhibit lesions of the brain ... Lesions of the brain microvessels , Lesions of ... of various kinds: white-matter hyperintensities and, more rarely, silent infarcts ...
... a genetic blood test and a five-minute functional MRI ... many of whom were destined to develop cognitive decline ... John Woodard, Ph.D., associate professor of psychology in ... of Gerontology at Wayne State University, is lead author ...
... Western Reserve University School of Medicine and Athersys, Inc. ... cord injury will be published today in the January ... study, by leading researchers from the Department of Neurosciences ... presents data supporting the potential therapeutic benefit of Athersys, ...
Cached Medicine News:Health News:Pitt study: End-of-life decisions take longer if patient hasn't shared wishes with family 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 3Health News:Migraines and headaches present no risk to cognitive function 2Health News:Migraines and headaches present no risk to cognitive function 3Health News:Wayne State University study predicts risk of memory loss in healthy, older adults 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 2Health News:Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury 3
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: